Live
FierceBiotechSmall pools, big ideas: How the rare disease community is reimagining clinical trialsBrady CorporationBrady India Champions a New Era of Industrial Safety at Safety Conclave 2026 - Machine MakerThermo FisherLobbying Update: $710,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver Quantitative10x Genomics BlogSaxonov, 10x Genomics CEO, sells $122k in stock - Investing.com10x Genomics BlogSaxonov, 10x Genomics CEO, sells $122k in stock - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) CEO sells 5,000 shares in 10b5-1 trade - Stock TitanFierceBiotechRyghtAI launches clinical site search engine to aid drug developers, CROs with trial designBioWorldSex differences shape gene activity across the human brainFierceBiotechRare Disease Research, myTomorrows team up to help patients access trialsFierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M dealFierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trialFierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTx
eLife Feb 5, 2026

Ly6G<sup>+</sup> granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis

Ly6G + granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis

Original
Body unavailable. Use the original source.